A phase 1/2 study of Adeno-Associated Virus Gene Therapy IC-100 for rhodopsin-mediated autosomal dominant Retinitis pigmentosa
Phase of Trial: Phase I/II
Latest Information Update: 01 Aug 2019
Price : $35 *
At a glance
- Drugs IC 100 (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions; Therapeutic Use
- Sponsors IVERIC bio
- 01 Aug 2019 According to an IVERIC bio media release, company plans to initiate this phase 1/2 study in second half of 2020.
- 06 Sep 2018 New trial record
- 22 Aug 2018 According to an OphthoTech Corporation media release, this phase 1/2 study is expected to start in 2020.